Paul Edward Kelly - Net Worth and Insider Trading
Paul Edward Kelly Net Worth
The estimated net worth of Paul Edward Kelly is at least $693,928 dollars as of 2024-04-26. Paul Edward Kelly is the Director of Relmada Therapeutics Inc and owns about 187,295 shares of Relmada Therapeutics Inc (RLMD) stock worth over $693,928. Details can be seen in Paul Edward Kelly's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Paul Edward Kelly has not made any transactions after 2022-04-04 and currently still holds the listed stock(s).
Transaction Summary of Paul Edward Kelly
Paul Edward Kelly Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Paul Edward Kelly owns 1 companies in total, including Relmada Therapeutics Inc (RLMD) .
Click here to see the complete history of Paul Edward Kelly’s form 4 insider trades.
Insider Ownership Summary of Paul Edward Kelly
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| RLMD | Relmada Therapeutics Inc | 2022-04-04 | director |
Paul Edward Kelly Latest Holdings Summary
Paul Edward Kelly currently owns a total of 1 stock. Paul Edward Kelly owns 187,295 shares of Relmada Therapeutics Inc (RLMD) as of April 4, 2022, with a value of $693,928.
Latest Holdings of Paul Edward Kelly
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| RLMD | Relmada Therapeutics Inc | 2022-04-04 | 187,295 | 3.71 | 693,928 |
Holding Weightings of Paul Edward Kelly
Paul Edward Kelly Form 4 Trading Tracker
According to the SEC Form 4 filings, Paul Edward Kelly has made a total of 10 transactions in Relmada Therapeutics Inc (RLMD) over the past 5 years, including 2 buys and 8 sells. The most-recent trade in Relmada Therapeutics Inc is the sale of 10,000 shares on April 4, 2022, which brought Paul Edward Kelly around $300,400.
Insider Trading History of Paul Edward Kelly
- 1
Paul Edward Kelly Trading Performance
GuruFocus tracks the stock performance after each of Paul Edward Kelly's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Paul Edward Kelly is 28.2%. GuruFocus also compares Paul Edward Kelly's trading performance to market benchmark return within the same time period. The performance of stocks bought by Paul Edward Kelly within 3 months outperforms 4 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Paul Edward Kelly's insider trading performs compared to the benchmark.
Performance of Paul Edward Kelly
Average Return
244.69%
Outperforming Transactions
80%
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 9.33 | 28.2 | 97 | 244.69 | 85.08 | 24.22 |
| Relative Return to S&P 500(%) | 9.64 | 26 | 92.47 | 233.65 | 67.24 | 10.96 |
Paul Edward Kelly Ownership Network
Ownership Network List of Paul Edward Kelly
Ownership Network Relation of Paul Edward Kelly
Paul Edward Kelly Owned Company Details
What does Relmada Therapeutics Inc do?
Who are the key executives at Relmada Therapeutics Inc?
Paul Edward Kelly is the director of Relmada Therapeutics Inc. Other key executives at Relmada Therapeutics Inc include director & Chief Executive Officer Sergio Traversa , Chief Financial Officer Chuck Ence , and Chief Medical Officer Cedric O'gorman .
Relmada Therapeutics Inc (RLMD) Insider Trades Summary
Over the past 18 months, Paul Edward Kelly made no insider transaction in Relmada Therapeutics Inc (RLMD). Other recent insider transactions involving Relmada Therapeutics Inc (RLMD) include a net purchase of 155,250 shares made by Sergio Traversa , a net purchase of 38,970 shares made by Chuck Ence , and a net purchase of 32,675 shares made by Maged Shenouda .
In summary, during the past 3 months, insiders sold 0 shares of Relmada Therapeutics Inc (RLMD) in total and bought 171,645 shares, with a net purchase of 171,645 shares. During the past 18 months, 0 shares of Relmada Therapeutics Inc (RLMD) were sold and 236,895 shares were bought by its insiders, resulting in a net purchase of 236,895 shares.
Relmada Therapeutics Inc (RLMD)'s detailed insider trading history can be found in Insider Trading Tracker table.
Relmada Therapeutics Inc Insider Transactions
Paul Edward Kelly Mailing Address
Above is the net worth, insider trading, and ownership report for Paul Edward Kelly. You might contact Paul Edward Kelly via mailing address: 300 East 56th Street, Apt 19e, New York, Ny 10022.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
